A report released today by Zacks Investment Research about Retrophin Inc (NASDAQ:RTRX) raises the target price to $25.00
- Updated: October 15, 2016
Yesterday Retrophin Inc (NASDAQ:RTRX) traded -3.79% lower at $22.45. The company’s 50-day moving average is $21.34 and its 200-day moving average is $17.87. The last stock close price is up 19.41% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 369,480 shares of RTRX traded hands, down from an average volume of 758,335
Reporting a possible upside of 0.11%, Zacks Investment Research bumped up the target of Retrophin Inc (NASDAQ:RTRX) to $25.00
Previously on 4/12/2016, BMO Capital Markets reported about Retrophin Inc (NASDAQ:RTRX) raised the target price from $0.00 to $25.00. At the time, this indicated a possible upside of 0.80%.
Recent Performance Chart
Retrophin Inc has price-earnings ratio of 8.67 with a one year low of $11.60 and a 52 week high of $24.57 and has a market cap of $0.
In addition to Zacks Investment Research reporting its target price, a total of 3 firms have issued a report on the stock. The consensus target price is $24.67 with 1 firm rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Retrophin Inc (NASDAQ:RTRX)
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.